Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison

M. Alavi, N.Z. Janjua, M. Chong, J. Grebely, E.J. Aspinall, H. Innes, H. Valerio, B. Hajarizadeh, P.C. Hayes, M. Krajden, J. Amin, M.G. Law, J. George, D.J. Goldberg, S.J. Hutchinson, G.J. Dore

Research output: Contribution to journalArticle

12 Downloads (Pure)

Abstract

This study evaluates trends in hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) incidence and survival in three settings, prior to introduction of direct-acting antiviral (DAA) therapies. Methods: HCV notifications from British Columbia (BC), Canada, New South Wales (NSW), Australia, and Scotland (1995-2011/2012/2013, respectively) were linked to HCC diagnosis data via hospital admissions (2001-2012/2013/2014, respectively), and mortality (1995-2013/2014/2015, respectively). Age-standardised HCC incidence rates were evaluated, associated factors were assessed using Cox regression, and median survival time after HCC diagnosis was calculated. Among 58,487, 84,529, and 31,924 people with HCV in BC, NSW, and Scotland, 734 (1.3%), 1,045 (1.2%), and 345 (1.1%) had an HCC diagnosis. Since mid-2000s, HCC diagnosis numbers increased in all jurisdictions. Age-standardised HCC incidence rates remained stable in BC and Scotland, and increased in NSW. The strongest predictor of HCC diagnosis was older age [birth <1945, aHR in BC 5.74, 95% CI 4.84, 6.82; NSW 9.26, 95% CI 7.93, 10.82; Scotland 12.55, 95% CI 9.19, 17.15]. Median survival after HCC diagnosis remained stable in BC (0.8 years in 2001-2006 and 2007-2011) and NSW (0.9 years in 2001-2006 and 2007-2013), and improved in Scotland (0.7 years in 2001-2006 to 1.5 years in 2007-2014). Across the settings, HCC burden increased, individual-level risk of HCC remained stable or increased, and HCC survival remained extremely low. These findings highlight the minimal impact of HCC prevention and management strategies during the interferon-based HCV treatment era, and form the basis for evaluating the impact of DAA therapy in the coming years.
Original languageEnglish
Pages (from-to)473-481
Number of pages9
JournalJournal of Viral Hepatitis
Volume25
Issue number5
Early online date30 Nov 2017
DOIs
Publication statusPublished - May 2018

Fingerprint

Hepatitis C
Hepatocellular Carcinoma
Incidence
British Columbia
New South Wales
Scotland
Hepacivirus
Antiviral Agents
South Australia
Interferons
Canada
Parturition

Keywords

  • HCV
  • liver disease
  • primary liver cancer
  • population-based
  • data linkage

Cite this

Alavi, M. ; Janjua, N.Z. ; Chong, M. ; Grebely, J. ; Aspinall, E.J. ; Innes, H. ; Valerio, H. ; Hajarizadeh, B. ; Hayes, P.C. ; Krajden, M. ; Amin, J. ; Law, M.G. ; George, J. ; Goldberg, D.J. ; Hutchinson, S.J. ; Dore, G.J. / Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison. In: Journal of Viral Hepatitis. 2018 ; Vol. 25, No. 5. pp. 473-481.
@article{e377c95777c04b28a2c0e0eadcf71d1e,
title = "Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison",
abstract = "This study evaluates trends in hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) incidence and survival in three settings, prior to introduction of direct-acting antiviral (DAA) therapies. Methods: HCV notifications from British Columbia (BC), Canada, New South Wales (NSW), Australia, and Scotland (1995-2011/2012/2013, respectively) were linked to HCC diagnosis data via hospital admissions (2001-2012/2013/2014, respectively), and mortality (1995-2013/2014/2015, respectively). Age-standardised HCC incidence rates were evaluated, associated factors were assessed using Cox regression, and median survival time after HCC diagnosis was calculated. Among 58,487, 84,529, and 31,924 people with HCV in BC, NSW, and Scotland, 734 (1.3{\%}), 1,045 (1.2{\%}), and 345 (1.1{\%}) had an HCC diagnosis. Since mid-2000s, HCC diagnosis numbers increased in all jurisdictions. Age-standardised HCC incidence rates remained stable in BC and Scotland, and increased in NSW. The strongest predictor of HCC diagnosis was older age [birth <1945, aHR in BC 5.74, 95{\%} CI 4.84, 6.82; NSW 9.26, 95{\%} CI 7.93, 10.82; Scotland 12.55, 95{\%} CI 9.19, 17.15]. Median survival after HCC diagnosis remained stable in BC (0.8 years in 2001-2006 and 2007-2011) and NSW (0.9 years in 2001-2006 and 2007-2013), and improved in Scotland (0.7 years in 2001-2006 to 1.5 years in 2007-2014). Across the settings, HCC burden increased, individual-level risk of HCC remained stable or increased, and HCC survival remained extremely low. These findings highlight the minimal impact of HCC prevention and management strategies during the interferon-based HCV treatment era, and form the basis for evaluating the impact of DAA therapy in the coming years.",
keywords = "HCV, liver disease, primary liver cancer, population-based, data linkage",
author = "M. Alavi and N.Z. Janjua and M. Chong and J. Grebely and E.J. Aspinall and H. Innes and H. Valerio and B. Hajarizadeh and P.C. Hayes and M. Krajden and J. Amin and M.G. Law and J. George and D.J. Goldberg and S.J. Hutchinson and G.J. Dore",
note = "Acceptance in SAN AAM: 12m embargo",
year = "2018",
month = "5",
doi = "10.1111/jvh.12837",
language = "English",
volume = "25",
pages = "473--481",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "John Wiley & Sons",
number = "5",

}

Alavi, M, Janjua, NZ, Chong, M, Grebely, J, Aspinall, EJ, Innes, H, Valerio, H, Hajarizadeh, B, Hayes, PC, Krajden, M, Amin, J, Law, MG, George, J, Goldberg, DJ, Hutchinson, SJ & Dore, GJ 2018, 'Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison', Journal of Viral Hepatitis, vol. 25, no. 5, pp. 473-481. https://doi.org/10.1111/jvh.12837

Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison. / Alavi, M.; Janjua, N.Z. ; Chong, M.; Grebely, J.; Aspinall, E.J.; Innes, H.; Valerio, H.; Hajarizadeh, B. ; Hayes, P.C. ; Krajden, M.; Amin, J.; Law, M.G. ; George, J.; Goldberg, D.J.; Hutchinson, S.J.; Dore, G.J.

In: Journal of Viral Hepatitis, Vol. 25, No. 5, 05.2018, p. 473-481.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison

AU - Alavi, M.

AU - Janjua, N.Z.

AU - Chong, M.

AU - Grebely, J.

AU - Aspinall, E.J.

AU - Innes, H.

AU - Valerio, H.

AU - Hajarizadeh, B.

AU - Hayes, P.C.

AU - Krajden, M.

AU - Amin, J.

AU - Law, M.G.

AU - George, J.

AU - Goldberg, D.J.

AU - Hutchinson, S.J.

AU - Dore, G.J.

N1 - Acceptance in SAN AAM: 12m embargo

PY - 2018/5

Y1 - 2018/5

N2 - This study evaluates trends in hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) incidence and survival in three settings, prior to introduction of direct-acting antiviral (DAA) therapies. Methods: HCV notifications from British Columbia (BC), Canada, New South Wales (NSW), Australia, and Scotland (1995-2011/2012/2013, respectively) were linked to HCC diagnosis data via hospital admissions (2001-2012/2013/2014, respectively), and mortality (1995-2013/2014/2015, respectively). Age-standardised HCC incidence rates were evaluated, associated factors were assessed using Cox regression, and median survival time after HCC diagnosis was calculated. Among 58,487, 84,529, and 31,924 people with HCV in BC, NSW, and Scotland, 734 (1.3%), 1,045 (1.2%), and 345 (1.1%) had an HCC diagnosis. Since mid-2000s, HCC diagnosis numbers increased in all jurisdictions. Age-standardised HCC incidence rates remained stable in BC and Scotland, and increased in NSW. The strongest predictor of HCC diagnosis was older age [birth <1945, aHR in BC 5.74, 95% CI 4.84, 6.82; NSW 9.26, 95% CI 7.93, 10.82; Scotland 12.55, 95% CI 9.19, 17.15]. Median survival after HCC diagnosis remained stable in BC (0.8 years in 2001-2006 and 2007-2011) and NSW (0.9 years in 2001-2006 and 2007-2013), and improved in Scotland (0.7 years in 2001-2006 to 1.5 years in 2007-2014). Across the settings, HCC burden increased, individual-level risk of HCC remained stable or increased, and HCC survival remained extremely low. These findings highlight the minimal impact of HCC prevention and management strategies during the interferon-based HCV treatment era, and form the basis for evaluating the impact of DAA therapy in the coming years.

AB - This study evaluates trends in hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) incidence and survival in three settings, prior to introduction of direct-acting antiviral (DAA) therapies. Methods: HCV notifications from British Columbia (BC), Canada, New South Wales (NSW), Australia, and Scotland (1995-2011/2012/2013, respectively) were linked to HCC diagnosis data via hospital admissions (2001-2012/2013/2014, respectively), and mortality (1995-2013/2014/2015, respectively). Age-standardised HCC incidence rates were evaluated, associated factors were assessed using Cox regression, and median survival time after HCC diagnosis was calculated. Among 58,487, 84,529, and 31,924 people with HCV in BC, NSW, and Scotland, 734 (1.3%), 1,045 (1.2%), and 345 (1.1%) had an HCC diagnosis. Since mid-2000s, HCC diagnosis numbers increased in all jurisdictions. Age-standardised HCC incidence rates remained stable in BC and Scotland, and increased in NSW. The strongest predictor of HCC diagnosis was older age [birth <1945, aHR in BC 5.74, 95% CI 4.84, 6.82; NSW 9.26, 95% CI 7.93, 10.82; Scotland 12.55, 95% CI 9.19, 17.15]. Median survival after HCC diagnosis remained stable in BC (0.8 years in 2001-2006 and 2007-2011) and NSW (0.9 years in 2001-2006 and 2007-2013), and improved in Scotland (0.7 years in 2001-2006 to 1.5 years in 2007-2014). Across the settings, HCC burden increased, individual-level risk of HCC remained stable or increased, and HCC survival remained extremely low. These findings highlight the minimal impact of HCC prevention and management strategies during the interferon-based HCV treatment era, and form the basis for evaluating the impact of DAA therapy in the coming years.

KW - HCV

KW - liver disease

KW - primary liver cancer

KW - population-based

KW - data linkage

U2 - 10.1111/jvh.12837

DO - 10.1111/jvh.12837

M3 - Article

VL - 25

SP - 473

EP - 481

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 5

ER -